120512-04-1

Basic information

• Product Name: Anastrozole IMpurity (alfa1 , alfa1, alfa3, alfa3-TetraMethyl-5-(1H-1,2,4-triazol-1-ylMethyl)-1,3-BenzenediacetaMide)
• Synonyms: Anastrozole IMpurity (alfa1 , alfa1, alfa3, alfa3-TetraMethyl-5-(1H-1,2,4-triazol-1-ylMethyl)-1,3-BenzenediacetaMide);Anastrozole Diamide;2,2'-(5-((1H-1,2,4-triazol-1-yl)methyl)-1,3-phenylene)bis(2-methylpropanamide)
• CAS NO: 120512-04-1
• Molecular Formula: C₁₇H₂₃N₅O₂
• Molecular Weight: 329.4
• Mol File: 120512-04-1.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: Amber Vial, Refrigerator, Under inert atmosphere
• Solubility: Chloroform (Slightly), DMSO, Methanol (Slightly)
• CAS DataBase Reference: Anastrozole IMpurity (alfa1 , alfa1, alfa3, alfa3-TetraMethyl-5-(1H-1,2,4-triazol-1-ylMethyl)-1,3-BenzenediacetaMide)(CAS DataBase Reference)
• NIST Chemistry Reference: Anastrozole IMpurity (alfa1 , alfa1, alfa3, alfa3-TetraMethyl-5-(1H-1,2,4-triazol-1-ylMethyl)-1,3-BenzenediacetaMide)(120512-04-1)
• EPA Substance Registry System: Anastrozole IMpurity (alfa1 , alfa1, alfa3, alfa3-TetraMethyl-5-(1H-1,2,4-triazol-1-ylMethyl)-1,3-BenzenediacetaMide)(120512-04-1)

Safety Data

• Hazardous Substances Data: 120512-04-1(Hazardous Substances Data)

Usage

Description

Anastrozole IMpurity (alfa1, alfa1, alfa3, alfa3-TetraMethyl-5-(1H-1,2,4-triazol-1-ylMethyl)-1,3-BenzenediacetaMide) is a chemical compound derived from Anastrozole, which is an aromatase inhibitor. It is characterized by its unique molecular structure, featuring a triazole ring and a benzene diacetamide backbone, with additional methyl groups at specific positions. This impurity is relevant in the pharmaceutical industry due to its potential impact on the efficacy and safety of Anastrozole-based medications.

Uses

Used in Pharmaceutical Industry:
Anastrozole IMpurity (alfa1, alfa1, alfa3, alfa3-TetraMethyl-5-(1H-1,2,4-triazol-1-ylMethyl)-1,3-BenzenediacetaMide) is used as an antineoplastic agent for the development and improvement of cancer treatments. As a derivative of Anastrozole, it has the potential to inhibit the aromatase enzyme, which is responsible for converting androgens to estrogens. This inhibition can help in the treatment of hormone receptor-positive breast cancer by reducing estrogen levels, thereby limiting the growth of cancer cells.
Additionally, the presence of this impurity in Anastrozole-based medications may require further investigation and quality control measures to ensure the safety and efficacy of the final product. This can involve the development of analytical methods for the detection and quantification of the impurity, as well as the optimization of synthesis processes to minimize its formation.

Relevant articles and documents

PROCESS FOR PREPARING PURE ANASTROZOLE

The present invention discloses two new related substances (6) and (7) of Anastrozole synthesis from Q. A. Salt (5) as in Scheme—1 and purification procedures to get Anastrozole (1) free from (6) and (7).